05/17 | BeiGene to Open Regional Office in Switzerland | MT |
05/17 | BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Swi.. | BU |
05/17 | BeiGene, Ltd. Announces the Opening of a New Regional Office in Basel, Switzerland | CI |
05/12 | BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hemato.. | BU |
05/11 | Asian ADRs Move Higher in Wednesday Trading | MT |
05/10 | Asian ADRs Climb Higher in Tuesday Trading | MT |
05/09 | Morgan Stanley Lowers BeiGene's Price Target to $300 From $338, Maintains Overweight Ra.. | MT |
05/09 | INSIDER SELL : BeiGene | MT |
05/05 | BeiGene Swings to Q1 Net Loss as Revenue Declines | MT |
05/05 | Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $306.6M, vs. Street Est of $300.4M | MT |
05/05 | BeiGene Reports First Quarter 2022 Financial Results | BU |
05/05 | BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
05/04 | BeiGene Says China Gives Conditional Approval to Blincyto Injection for Pediatric Acute.. | MT |
05/04 | BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for P.. | BU |
05/04 | Beigene Announces the Approval in China of BLINCYTO® for Injection for Pediatric Patien.. | CI |
04/29 | BeiGene Breaks Ground on Flagship US Facility in New Jersey; Shares Climb | MT |
04/29 | BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton Wes.. | BU |
04/29 | Beigene Breaks Ground on New Manufacturing and Clinical R&D Center At the Princeton Wes.. | CI |
04/28 | BEIGENE : Financial Information - Form 8-K | PU |
04/28 | BeiGene's Brukinsa Secures Uruguay's Approval For Lymphoma, Waldenstrom's Macroglobulin.. | MT |
04/28 | BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, .. | BU |
04/28 | Beigene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, .. | CI |
04/27 | BeiGene, Ltd. Announces Global Phase 3 Trial of PD-1 Inhibitor, Tislelizumab, in Combin.. | CI |
04/27 | BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual.. | BU |
04/27 | BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual.. | CI |
04/27 | Global Phase 3 Trial of BeiGene's PD-1 Inhibitor, Tislelizumab, in Combination with Che.. | BU |
04/27 | BeiGene Phase 3 Trial for Tislelizumab Meets Primary Endpoint | DJ |
04/26 | BeiGene Introduces Global Environmental, Social, and Governance Strategy | BU |
04/25 | Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene | AQ |
04/25 | Biocytogen Signs Renmab /Renlite Licensing Agreement with Beigene | CI |
04/21 | US Adds Luckin Coffee, Li Auto, Others to SEC's List of HFCAA Noncompliant Firms | MT |
04/21 | BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Can.. | BU |
04/20 | BEIGENE : China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamo.. | PU |
04/19 | BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tis.. | BU |
04/19 | BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tis.. | CI |
04/18 | Beigene's Cancer Drug Gets Regulator Approval in China | MT |
04/15 | China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell.. | BU |
04/15 | BeiGene, Ltd. Announces China National Medical Products Administration Approves Tisleli.. | CI |
04/15 | BeiGene Gets China Approval for Tislelizumab Cancer Treatment | DJ |
04/12 | BEIGENE : Announces European Medicines Agency Acceptance of Marketing Authorization Applic.. | PU |
04/12 | Morgan Stanley Adjusts BeiGene's Price Target to $338 from $330, Keeps Overweight Ratin.. | MT |
04/11 | Asian ADRs Move Lower in Monday Trading | MT |
04/11 | Beigene Announces IRC Determines Brukinsa® (Zanubrutinib) Demonstrates Superior Overall.. | CI |
04/11 | BeiGene's Brukinsa Improves Overall Response Rate in Chronic Lymphocytic Leukemia in Ph.. | MT |
04/11 | IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Ver.. | BU |
04/08 | BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors .. | BU |
04/08 | BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors .. | CI |
04/06 | BeiGene Says European Regulator Accepts Marketing Authorization Applications for Tislel.. | MT |
04/06 | BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Appli.. | BU |
04/06 | Beigene, Ltd. Announces European Medicines Agency Acceptance of Marketing Authorization.. | CI |
04/04 | China’s Securities Watchdog Eases Rules on Financial Inspections of Offshore List.. | MT |
04/03 | SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beige.. | PR |
04/01 | Baidu Explores Options Amid US Delisting Risk; Hong Kong Shares Fall 6% | MT |
03/31 | Hong Kong Stocks Retreat from Four-Week High; Two Out of Three Newcomers Gain in Tradin.. | MT |
03/25 | SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beige.. | PR |
03/25 | BEIGENE : Current Report (Form 8-K) | PU |
03/25 | Hong Kong Stocks Finish Lower; Weibo Slides 5% | MT |
03/25 | Weibo to Explore All Options Amid US Delisting Risk | MT |
03/24 | Asian ADRs Move Lower in Thursday Trading | MT |
03/22 | Beijing Asks Alibaba, JD.com, Others to Brace For More US Audit Disclosures | MT |
03/22 | Exclusive - Chinese regulators ask some U.S.-listed firms to prepare for audit disclosu.. | RE |
03/22 | Chinese regulators ask some U.S.-listed firms to prepare for audit disclosures - source.. | RE |
03/17 | BEIGENE : China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-Hi.. | PU |
03/17 | SVB Leerink Cuts BeiGene to Market Perform From Outperform, Price Target to $177 From $.. | MT |
03/16 | SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beige.. | PR |
03/16 | ADRs End Higher; Bilibili Gains 48% | DJ |
03/16 | BeiGene Up Over 22%, on Pace for Largest Percent Increase Since November 2019 -- Data T.. | DJ |
03/15 | SECTOR UPDATE : Health Care Stocks Gaining Steam in Late Trade | MT |
03/15 | SECTOR UPDATE : Health Care Stocks Advancing Tuesday | MT |
03/15 | BeiGene, Medison Pharma Say Israel Approves Brukinsa to Treat Waldenstrom's Macroglobul.. | MT |
03/15 | BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA.. | BU |
03/15 | BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA.. | CI |
03/14 | Chinese Regulators Grant Conditional OK to BeiGene's Solid Tumor Treatment | MT |
03/13 | Yum China, Four Others Face Delisting Risk in US Over Auditing Violations | MT |
03/11 | Yum China, BeiGene Among Five Firms Facing Delisting Over Audit Review Act -- Shares Ex.. | MT |